Table 2.
Characteristics of the BRAF screening studies included in the meta-analysis
| Author | Year | Location |
Sex
(%men) |
Mean age (%) | Sample size (N) |
Tumor Stage*
1 & 2 |
Tumor Stage*
3 & 4 |
Tumor Location* (colon) | Tumor Location* (rectum) | Tumor Grade* (poorly) | Tumor Grade* (Moderate) | Tumor Grade* (Well) | Method |
Total BRAF Mutation
(%) |
| Brim [43] | 2008 | Shiraz | 64.0 | 59.80 | 53 | 23.0 | 77.0 | NR | NR | 4.0 | 42.0 | 54.0 | Sequencing | 2.0 |
| Dolatkhah 1 [48] | 2014 | Tabriz | 76.7 | 61.77 | 30 | 36.6 | 46.7 | NR | NR | 6.7 | 26.7 | 50.0 | Sequencing | 0.0 |
| Dolatkhah 2 [49] | 2016 | Tabriz | 65.0 | 61.90 | 100 | 37.0 | 29.0 | 72.0 | 28.0 | 3.0 | 22.0 | 49.0 | Sequencing | 0.0 |
| Ghaffarpour [44] | 2011 | Tehran | 37.0 | 61.30 | 27 | 59.2 | 40.8 | NR | NR | 7.4 | 25.9 | 66.6 | Sequencing | 3.7 |
| Javadi [45] | 2014 | Shiraz | 55.0 | 59.80 | 100 | 66.0 | 34.0 | 100.0 | 0.0 | 0.0 | 17.0 | 83.0 | Sequencing | 0.0 |
| Naghibalhossaini [50] | 2011 | Shiraz | 65.4 | NR | 110 | 64.5 | 35.5 | NR | NR | 43.6 | 40.0 | 4.5 | PCR-RFLP/SSCP/ Sequencing | 0.0 |
| Mohammadi Asl [46] | 2014 | Ahwaz | 45.0 | 44.25 | 80 | NR | NR | NR | NR | NR | NR | NR | PCR-RFLP/sequencing | 46.3 |
| Molaie [47] | 2016 | Tehran | 56.4 | 51.00 | 85 | NR | NR | NR | NR | NR | NR | NR | Sequencing | 0.0 |
| Payandeh 2 [51] | 2015 | Kermanshah | 57.6 | 57.27 | 5 | 0.0 | 100 | 60.6 | 39.4 | NR | NR | NR | HRMA/AS-PCR/ pyrosequencing | 0.0 |
N: Number, NR: Not reported, *: Percentage of all samples
N: Number, NR: Not reported, *: Percentage of all samples